Posted by Michael Wonder on 30 Oct 2022
Pharming announces EMA validates its marketing authorisation application under accelerated assessment for leniolisib
28 October 2022 - Marketing authorisation in the European Economic Area anticipated in H1 2023
Pharming announces today that its Marketing Authorisation application for leniolisib has been validated for scientific evaluation under an accelerated assessment by the EMA's CHMP.
